Products for Research Use Only
RegisterLogin

Glatiramer (acetate)

CAT: 0804-HY-109520-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109520-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3].
CAS Number
147245-92-9
UNSPSC
12352005
Hazard Statement
H315, H317, H319, H334
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/glatiramer-acetate.html
Purity
98.0
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
OC(CC[C@H](N)C(O)=O)=O.OC([C@@H](N)CC1=CC=C(O)C=C1)=O.OC([C@@H](N)C)=O.NCCCC[C@H](N)C(O)=O.O=C(C)O.[x].[x].[x].[x].[x]
Molecular Formula
(C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2) x.xC2H4O2
Precautions
H315, H317, H319, H334
References & Citations
[1]McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29 (5) :425-432.|[2]Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2 (Suppl 2) :14593-14598.|[3]Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110.|[4]Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [published correction appears in Proc Natl Acad Sci U S A. 2005 Aug 23;102 (34) :12288]. Proc Natl Acad Sci U S A. 2003;100 (24) :14157-14162.|[5]Lalive PH, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011 May;25 (5) :401-14.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName
HY-166875SApramycin acetate-d7 (acetate)
HY-134716Methyl acetate-PEG1-methyl acetate
HY-W127616-01β-Sitosterol acetate, 40% (contains Campesterol acetate)
HY-P4091A-01LSD (acetate)
HY-P2483B-01Octaarginine (acetate)
HY-P10959A-01Macupatide (acetate)
HY-P10517A-01Sifuvirtide (acetate)
HY-P0013A-01Antide (acetate)
HY-N15333β-Terpinyl acetate
HY-172299-01Delmadinone acetate

Alternative Products

CatalogName
FG138110-01Glatiramer acetate
CS-T-103954Glatiramer Acetate-Dx
AR-G01793-01Glatiramer Acetate Tetrapeptide Standard
MBS7277828-01Monkey Glatiramer Acetate ELISA Kit
MBS7276206-01Mouse Glatiramer Acetate ELISA Kit
KOD1024KRIBIOLISA™ Glatiramer Acetate (COPAXONE) ELISA
GTR10468573Goat Glatiramer Acetate ELISA kit

Popular Products